Neutralization of heparin activity by neutrophil lactoferrin

Lactoferrin is a prominent component of neutrophil secondary granules, and its blood concentration is increased in certain inflammatory diseases. In contrast to the well-described biochemical characterization of lactoferrin as an iron-binding protein, its physiologic role in the regulation of inflammation and other host defense mechanisms is unclear. In this report, we provide evidence that lactoferrin has a potent heparin-neutralizing activity during thrombin inhibition by the serine proteinase inhibitors (serpins) antithrombin and heparin co-factor II. Activated neutrophil supernatant, which contains lactoferrin and other heparin-binding proteins, could neutralize the heparin-dependent antithrombin-thrombin inhibition reaction. The addition of lactoferrin to plasma corrected the heparin- induced prolongation of blood plasma coagulation as measured by the activated partial thromboplastin time (aPTT). Treatment of whole blood with specific inflammatory mediators, fMLP, lipopolysaccharide (LPS), and tumor necrosis factor-alpha (TNF-alpha) increased the concentration of both plasma lactoferrin and platelet factor 4 while inhibiting the blood anticoagulant activity of heparin as measured by the aPTT. These results suggest that the prothrombotic sequelae of some inflammatory processes may be partly due to various agonists that release neutrophil lactoferrin, which can then neutralize glycosaminoglycan-dependent serpin-thrombin inhibition reactions.

[1]  E. Baker,et al.  Structure of the recombinant N-terminal lobe of human lactoferrin at 2.0 A resolution. , 1993, Journal of molecular biology.

[2]  J. Djeu,et al.  Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans , 1992, Infection and immunity.

[3]  J. Cassiman,et al.  Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. , 1992, The Journal of biological chemistry.

[4]  D. Monroe,et al.  Microplate coagulation assays. , 1992, BioTechniques.

[5]  E. Baker,et al.  Studies of the N-terminal half of human lactoferrin produced from the cloned cDNA demonstrate that interlobe interactions modulate iron release. , 1992, The Journal of biological chemistry.

[6]  C. D'Anastasio,et al.  Plasma lactoferrin as a marker of infection in elderly individuals , 1992, Aging.

[7]  K. Ucar,et al.  Hypercoagulability and thrombosis. , 1992, Hematology/oncology clinics of North America.

[8]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[9]  J. Gallin,et al.  Absence of the Largest Platelet-von Willebrand Multimers in a Patient with Lactoferrin Deficiency and a Bleeding Tendency , 1992, Thrombosis and Haemostasis.

[10]  C. Esmon.  The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  R. Colman,et al.  Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. , 1992, The Journal of laboratory and clinical medicine.

[12]  H. Roberts,et al.  New perspectives on the coagulation cascade. , 1992, Hospital practice.

[13]  D. Tollefsen,et al.  The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. , 1991, The Journal of biological chemistry.

[14]  Simon C Watkins,et al.  Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta , 1990, The Journal of cell biology.

[15]  W. Novotny,et al.  Regulation of coagulation by a multivalent Kunitz-type inhibitor. , 1990, Biochemistry.

[16]  Edward N. Baker,et al.  Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins , 1990, Nature.

[17]  M. Walport,et al.  Plasma lactoferrin and neutrophil elastase in rheumatoid arthritis and systemic lupus erythematosus. , 1990, British journal of rheumatology.

[18]  A. Cardin,et al.  Molecular Modeling of Protein‐Glycosaminoglycan Interactions , 1989, Arteriosclerosis.

[19]  I. Goldstein,et al.  Bacterial-lipopolysaccharide-induced release of lactoferrin from human polymorphonuclear leukocytes: role of monocyte-derived tumor necrosis factor alpha , 1987, Infection and Immunity.

[20]  J. Marcum,et al.  Anticoagulantly Active Heparan Sulfate Proteoglycan and the Vascular Endothelium , 1987, Seminars in thrombosis and hemostasis.

[21]  J. Loscalzo,et al.  The interaction of platelet factor four and glycosaminoglycans. , 1985, Archives of biochemistry and biophysics.

[22]  M. Griffith,et al.  Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. , 1985, The Journal of biological chemistry.

[23]  F. Schoentgen,et al.  Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. , 1984, European journal of biochemistry.

[24]  T. Coates,et al.  Plasma lactoferrin reflects granulocyte activation in vivo. , 1983, Blood.

[25]  J. Lewis,et al.  Disseminated Intravascular Coagulation , 1980, Thrombosis and Haemostasis.

[26]  O. Hernell,et al.  Isolation of lactoferrin from human whey by a single chromatographic step , 1980, FEBS letters.

[27]  J. Bucher,et al.  Isolation and characterization of granulocyte lysosomal proteins and study of their effects on the clotting system , 1979, American journal of hematology.

[28]  D. Johnson,et al.  The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. , 1979, The Journal of biological chemistry.

[29]  R. Rosenberg,et al.  Structure-function relationships of heparin species. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Rosenberg,et al.  The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.

[31]  R. Lundblad.  A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride. , 1971, Biochemistry.

[32]  E. Schonne,et al.  LACTOFERRIN, AN IRON-BINBING PROTEIN NI NEUTROPHILIC LEUKOCYTES , 1969, The Journal of experimental medicine.

[33]  H. Roberts,et al.  Anti-heparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes. , 1968, Blood.

[34]  F. Church,et al.  Antithrombin: structure and function. , 1991, Seminars in hematology.

[35]  N. Sakuragawa,et al.  Histidine-rich glycoprotein inhibits the antithrombin activity of heparin cofactor II in the presence of heparin or dermatan sulfate. , 1985, Thrombosis research.